Alphamab Oncology
HKEX:9966
Alphamab Oncology
Revenue
Alphamab Oncology
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Alphamab Oncology
HKEX:9966
|
Revenue
¥218.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥9.6B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Revenue
¥6.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
266%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥5.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Revenue
¥49.7B
|
CAGR 3-Years
53%
|
CAGR 5-Years
65%
|
CAGR 10-Years
50%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Revenue
¥1.9B
|
CAGR 3-Years
51%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
See Also
What is Alphamab Oncology's Revenue?
Revenue
218.8m
CNY
Based on the financial report for Dec 31, 2023, Alphamab Oncology's Revenue amounts to 218.8m CNY.
What is Alphamab Oncology's Revenue growth rate?
Revenue CAGR 1Y
31%
Over the last year, the Revenue growth was 31%.